Interestingly, interleukin-6 (IL-6)-mediated STAT3 activation has been found to up-regulate PTTG1, thus leading to the malignant behaviors of prostate cancer cells (Huang et al., 2018). This evidence concerns the gene STAT3 and prostate carcinoma.